BioNTech tops Q4 expectations

BioNTech SE (NASDAQ: BNTX) reported Q4 2022 financial results on Monday.

The German pharmaceutical company reported revenue of $4.563 billion for the quarter, topping analyst estimate of $3.897 billion.

Earnings per share (EPS) also beat analyst estimates at $9.876 per share vs. $8.296 EPS expected.

CEO commentary

”We made significant progress in 2022 by advancing our pipeline and launching the world’s first Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine. In addition, multiple new modalities achieved encouraging clinical data and we progressed nine new programs into clinical trials,” said professor Ugur Sahin, M.D., CEO and Co-Founder of BioNTech said in a press release.

”As we look to 2023 and beyond, we plan to continue investing in our transformation with a focus on building commercial capabilities in oncology and working towards registrational trials. Our mid-term goal is to seek approval for multiple oncology products in cancer indications with high unmet medical need,” he added.

The stock was down by -3.59% at market close on Tuesday at $123.19 per share.

Stock performance

• 1 month: -5.55%
• 3 months: -29.76%
• Year-to-date: -17.72%
• 1 year: -25.70%

BioNTech SE price targets

• HC Wainwright & Co.: $210
• JP Morgan: $142
• Goldman Sachs: $156
• Morgan Stanley: $216
• B of A Securities: $239
• SVB Leerink: $224
• Canaccord Genuity: $192

BioNTech SE is the 576^th largest company in the world with a market cap of $29.99 billion.

You can trade BioNTech SE (NASDAQ: BNTX) and many other stocks from the NYSE, NASDAQ, HKEX, ASX, LSE and DE with GO Markets as a Share CFD.

Sources: BioNTech SE, TradingView, MarketWatch, MetaTrader 5, Benzinga, CompaniesMarketCap